| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
13,567 |
10,913 |
$2.01M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
24,479 |
18,269 |
$962K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
6,019 |
3,785 |
$563K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,108 |
9,074 |
$398K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,698 |
8,550 |
$282K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
171 |
139 |
$135K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
7,805 |
3,724 |
$95K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
6,039 |
2,824 |
$89K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
7,867 |
3,754 |
$63K |
| 97012 |
|
7,744 |
3,658 |
$57K |
| 97014 |
|
7,140 |
3,514 |
$50K |
| 98940 |
|
2,110 |
1,071 |
$25K |
| 84311 |
|
4,143 |
3,378 |
$24K |
| 62323 |
|
224 |
158 |
$22K |
| 82570 |
|
4,135 |
3,325 |
$18K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
225 |
156 |
$14K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
773 |
660 |
$9K |
| 95923 |
|
107 |
88 |
$9K |
| 95924 |
|
102 |
85 |
$8K |
| 93923 |
|
121 |
88 |
$8K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
107 |
76 |
$5K |
| 99442 |
|
301 |
230 |
$4K |
| 99215 |
Prolong outpt/office vis |
101 |
73 |
$3K |
| 20610 |
|
68 |
50 |
$2K |
| 81003 |
|
2,397 |
1,812 |
$339.01 |
| 72100 |
|
13 |
12 |
$263.56 |
| G0281 |
Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care |
406 |
134 |
$0.00 |